MARKET

NEXI

NEXI

Neximmune, Inc.
NASDAQ
3.430
-0.215
-5.90%
Closed 16:21 04/23 EDT
OPEN
3.590
PREV CLOSE
3.645
HIGH
3.590
LOW
3.430
VOLUME
6.79K
TURNOVER
0
52 WEEK HIGH
28.69
52 WEEK LOW
1.250
MARKET CAP
4.70M
P/E (TTM)
-0.1113
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NEXI last week (0415-0419)?
Weekly Report · 2d ago
NEXI Stock Earnings: NexImmune Reported Results for Q4 2023
NexImmune just reported results for the fourth quarter of 2023. The company did not report any revenue for the quarter. NexImmune reported earnings per share of -$4.99 and no revenue at the quarter's end. InvestorPlace Earnings is a project that automates coverage of quarterly earnings.
Investorplace · 04/17 03:53
Neximmune, Inc. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Press release · 04/17 01:00
Weekly Report: what happened at NEXI last week (0408-0412)?
Weekly Report · 04/15 10:39
Weekly Report: what happened at NEXI last week (0401-0405)?
Weekly Report · 04/08 10:42
NexImmune Announces Leadership Shift in Financial Management
TipRanks · 04/05 20:24
NEXIMMUNE INC: APPOINTED ALBERT N. MARCHIO II AS INTERIM CFO
Reuters · 04/05 20:08
XXII, GRIN and XTIA are among mid-day movers
On the Move XXII, GRIN and XTIA are among mid-day movers. MediaCo Holding and 22nd Century Group are among the biggest gainers. NewGenIvf, Kenon and HWH are among those losing ground in the biotech sector.
Seeking Alpha · 04/05 18:55
More
About NEXI
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.

Webull offers Neximmune Inc stock information, including NASDAQ: NEXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEXI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NEXI stock methods without spending real money on the virtual paper trading platform.